Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Vandana Singh

4606 posts
Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Biotech
  • Equities
  • Financing
  • General
  • Health Care
  • Movers
  • News
  • Offerings
  • Trading Ideas

Why Is Regenerative Medicine-Focused Surrozen Stock Trading Lower On Monday?

By Vandana Singh
April 1, 1:14 PM
Surrozen engages in a private placement, aiming to raise approximately $192.5 million in gross proceeds. Updates on SZN-043 Phase 1a trial reveal promising safety, tolerability, and effects on liver function.

SRZN

Read More
2 minute read
  • Biotech
  • Equities
  • General
  • Health Care
  • News

Micro-Cap Cancer Focused Candel Therapeutics Highlights Encouraging Data From Brain Tumor Immunotherapy

By Vandana Singh
April 1, 12:49 PM
Data from Candel Therapeutics on CAN-3110, a promising viral immunotherapy for recurrent high-grade glioma. Discover survival rates and potential advancements in cancer treatment.

CADL

Read More
2 minute read
  • Equities
  • FDA
  • General
  • Health Care
  • Large Cap
  • Movers
  • News
  • Trading Ideas

Medical Devices Giant Baxter Secures FDA Approval For New Infusion Pump System

By Vandana Singh
April 1, 12:38 PM
FDA clears Baxter's Novum IQ LVP & SYR infusion pumps with Dose IQ Safety Software, streamlining training & reducing cognitive burden. Explore enhanced safety features & EMR interoperability.

BAX

Read More
2 minute read
  • Biotech
  • Equities
  • FDA
  • General
  • Health Care
  • Movers
  • News
  • Trading Ideas

FDA Presses Delay Button For Applied Therapeutics’ First Potential Marketed Drug For Rare Disease

By Vandana Singh
April 1, 12:30 PM
FDA extends the review period for Applied Therapeutics' NDA for govorestat, targeting Classic Galactosemia treatment. The new action date is set for November 28, 2024. Applied Therapeutics anticipates a decision from EMA in Q4 2024.

APLT

Read More
2 minute read
  • Biotech
  • Equities
  • General
  • Health Care
  • Movers
  • News
  • Trading Ideas

Disc Medicine Stock Plunges As Light Sensitivity Treatment Data Confounded Due To Outsized Placebo Response

By Vandana Singh
April 1, 10:52 AM
Disc Medicine releases AURORA Phase 2 study data on bitopertin for Erythropoietic Protoporphyria. Significant reductions in PPIX levels and improvements in phototoxic reactions observed with bitopertin treatment.

DISC

Read More
2 minute read
  • Biotech
  • Equities
  • General
  • Health Care
  • Large Cap
  • News

One Good, One Bad News For Bristol Myers Squibb’s Marketed Drugs: Details

By Vandana Singh
April 1, 9:44 AM
Bristol Myers Squibb shares update on Phase 3 YELLOWSTONE trial for Zeposia (ozanimod) in Crohn's disease. Primary endpoint not met, safety consistent. Also, positive Phase 3 results for Krazati (adagrasib) in KRASG12C-mutated NSCLC.

BMY

Read More
2 minute read
  • Equities
  • General
  • Health Care
  • Management
  • News

Investor Activism: Elanco Animal Health Settles with Ancora, Adds New Board Members

By Vandana Singh
April 1, 8:45 AM
Elanco Animal Health settles with Ancora, expanding board to 14 members, including Ancora's nominees Craig Wallace and Kathy Turner. Ancora's significant stake in Elanco, approximately $250 million, has driven discussions on board restructuring and CEO succession planning.

ELAN

Read More
2 minute read
  • Analyst Color
  • Biotech
  • General
  • Health Care
  • Initiation
  • Movers
  • News
  • Trading Ideas

Scholar Rock Is A Potential M&A Target, Its Exploration of Obesity Market Garners Interest: Analyst

By Vandana Singh
March 28, 2:42 PM
Raymond James has initiated coverage on Scholar Rock Holding (NASDAQ:SRRK), supported by the potential value with a couple of key programs utilizing selective myostatin inhibition to 

NVO

Read More
2 minute read
  • Analyst Color
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

Amgen’s Diversified Portfolio To Drive Long-Term Growth, Though Uncertainties Loom, Analyst Says

By Vandana Singh
March 28, 2:28 PM
Raymond James resumes coverage of Amgen highlighting its diversified portfolio and strong presence across therapeutic areas for sustainable long-term growth. Innovative pipeline in oncology, rare diseases, and obesity offers promise, though uncertainties remain."

AMGN

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Movers
  • News

4D Molecular Therapeutics Outlines Pivotal Development Plans For Cystic Fibrosis, Rare Inherited Disease

By Vandana Singh
March 28, 2:04 PM
4D Molecular Therapeutics' latest advancements in CF treatment. Get insights into their 4D-710 aerosolized genetic medicine for cystic fibrosis lung disease, including Phase 1/2 AEROW trial updates and Phase 3 clinical trial preparations.

FDMT

Posts pagination

Previous 1 … 47 48 49 … 461 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service